Showing 4111-4120 of 5623 results for "".
- Xequel Bio Announces Positive Results from Phase 1b Study of iNexin, a Novel aCT1 Ophthalmic Solutionhttps://modernod.com/news/xequel-bio-announces-positive-results-from-phase-1b-study-of-inexin-a-novel-act1-ophthalmic-solution/2480963/Xequel Bio announced positive results from its phase 1b clinical trial with iNexin (aCT1 ophthalmic solution) for the treatment of corneal injury in patients with dry eye disease. The study demonstrated that iNexin was safe and well-tolerated at the doses tested, and ear
- Zeiss Ventures Invests in Morrow Eyewearhttps://modernod.com/news/zeiss-ventures-invests-in-morrow-eyewear/2480961/Zeiss Ventures has invested in Morrow, a high-tech start-up from Belgium developing autofocal glasses that allow people to switch between near vision and distance vision at the touch of a button. The innovative liquid crystal technology is embedded between two ultra-precise, thin-c
- Bausch + Lomb Announces Efficiency-Enhancing Upgrades for Stellaris Elite Vision Enhancement Systemhttps://modernod.com/news/bausch-lomb-announces-efficiency-enhancing-upgrades-for-stellaris-elite-vision-enhancement-system/2480960/Bausch + Lomb announced the first in a series of upgrades for the Stellaris Elite vision enhancement system designed to enhance efficiency. The upgrades include an increase to the maximum vacuum setting from 600 to 660 mmHg and an enhancement to the removable valve caps in the troc
- Samsara Vision Announces First US Surgeries of the SING IMT for AMD as Part of the CONCERTO Studyhttps://modernod.com/news/samsara-vision-announces-first-us-surgeries-of-the-sing-imt-for-aamd-as-part-of-the-concerto-study/2480955/Samsara Vision announced the completion of the first US surgeries of its SING IMT (Smaller-Incision New-Generation Implantable Miniature Telescope), as part of the CONCERTO clinical study, a US-based FDA study to evaluate improvements in visual acuity and safety of the device
- Global Data: Increasing Cataract Surgical Rates Will Drive Artificial Lenses Market to Reach $4.7 Billion by 2030https://modernod.com/news/global-data-increasing-cataract-surgical-rates-will-drive-artificial-lenses-market-to-reach-47-billion-by-2030/2480953/The global market for IOLs is forecast by GlobalData to steadily grow from $4.3 billion in 2021 to $4.7 billion by the end of the decade. The data and analytics company notes that this growth is primarily driven by the growing capacity of many hospitals and clinics across all regions to perform m
- RetinalGeniX Technologies Acquires DNA/GPS Inc.https://modernod.com/news/retinalgenix-technologies-acquires-dnagps-inc/2480949/RetinalGeniX Technologies announced the acquisition of DNA/GPS. Terms of the deal were not disclosed. The acquisition gives RetinalGeniX the rights to the platform technology designed by Larry Perich, MD, which is designed to al
- OliX Pharmaceuticals Announces IND Submission to FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trialhttps://modernod.com/news/olix-pharmaceuticals-announces-ind-submission-to-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial/2480945/OiX Pharmaceuticals announced the submission of an investigational new drug (IND) application to the FDA to evaluate the safety and tolerability of OLX10212 for the treatment of advanced age-related macular degeneration (AMD). The objective of this phase 1 study is to determine the safety an
- NPR Report: He and His Wife Both Got Cataract Surgery. His Bill Was 20 times Higher Than Hershttps://modernod.com/news/npr-report-he-and-his-wife-both-got-cataract-surgery-his-bill-was-20-times-higher-than-hers/2480934/A NPR report shares an example of the factors involved in how insurance companies determine reimbursement for cataract surgery. The articl
- LumiThera Presents New Data from LIGHTSITE III Trial Showing Improvement in Vision in Intermediate Dry AMDhttps://modernod.com/news/lumithera-presents-new-data-from-lightsite-iii-trial-showing-improvement-in-vision-in-intermediate-dry-amd/2480930/LumiThera announced detailed findings in its LIGHTSITE III, multicenter clinical trial in non-neovascular age-related macular degeneration (AMD) subjects treated with photobiomodulation (PBM) using the Valeda Light Delivery System. LIGHTSITE III, a prospective, double-masked,
- BRIM Biotechnology Enters Trading in Taiwanhttps://modernod.com/news/brim-biotechnology-enters-otc-trading-in-taiwan/2480926/BRIM Biotechnology has entered OTC trading in Taiwan on June 23, 2022. Established in 2013, BRIM is a clinical-stage company developing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases. BRIM has several novel drug products